Is Zoetis a rare opportunity, or has the business fundamentally changed?

Zoetis has fallen dramatically after weaker US companion-animal sales, market-share losses, more competition and repeated guidance cuts.

Those problems are real. But the valuation now looks unusually low for the global leader in animal health—a business with strong brands, high margins, recurring demand, global distribution and a broad portfolio across pets and livestock.

The main thing I’m trying to understand is whether Zoetis is experiencing a difficult but temporary reset, or whether something more fundamental has changed.

Are veterinarians switching away from products like Apoquel, Cytopoint, Simparica Trio and Librela because competing products are genuinely better? Or is Zoetis mainly losing ground because of pricing, rebates and weaker sales execution?

I’m also curious whether these problems are limited to a few major US products or whether there are signs of weakness across the wider business. The international and livestock divisions still appear relatively strong, so how much do they protect the company if the US pet business remains weak?

The pipeline is another important question. Does Zoetis have enough promising new products to replace slowing franchises and restore growth, or is management relying too heavily on extensions of existing products?

Finally, what would convince you that the moat is still intact? Stabilising prescription trends? Recovering clinic market share? Successful launches? No further guidance cuts? And what evidence would instead suggest that Zoetis has permanently lost pricing power or competitive strength?

At this valuation, the market seems to be expecting a long period of weak growth. Is that realistic—or is it underestimating the company’s ability to adapt and recover?